Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
Crossref DOI link: https://doi.org/10.1007/s00345-016-1895-2
Published Online: 2016-07-14
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Arslan, Cagatay
License valid from 2016-07-14